aTyr Pharma's partner Kyorin doses first patient in Phase 3 EFZO-FIT study; receives $10M milestone

aTYR PHARMA INC

Kyorin dosed first patient in Japan in global pivotal Phase 3 EFZO-FIT trial of efzofitimod for pulmonary sarcoidosis.
Milestone payment of $10M triggered under Kyorin agreement; total upfront and milestones to date $20M.
aTyr eligible for up to $155M additional development, regulatory, and sales milestones plus royalties on Japan net sales.
Kyorin holds exclusive rights to develop and commercialize efzofitimod for all interstitial lung diseases in Japan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.